PEOPLE - HIG Ventures makes appointment:
This article was originally published in Clinica
Michael Gutch has been appointed to the life sciences investment team of HIG Ventures (the venture capital wing of HIG Capital). Mr Gutch, who has a PhD in cellular and molecular pathology and an MBA will focus on medical device and biopharma opportunities. He joins the Miami, Florida-based team from Lilly Ventures (Eli Lilly's capital group), where he was a principal.
You may also be interested in...
With many non-CE marked products being allowed onto various EU member state markets, who is going to monitor compliance? TÜV-SÜD’s Bassil Akra calls for cooperation to avoid unsafe products being used on patients.
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.